Ignite Creation Date:
2025-12-24 @ 10:58 PM
Ignite Modification Date:
2025-12-25 @ 8:27 PM
Study NCT ID:
NCT05388669
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-19
First Post:
2022-05-19
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Sponsor:
Janssen Research & Development, LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-08-05
Start Date Type:
ACTUAL
Primary Completion Date:
2024-01-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-05-19
First Submit QC Date:
None
Study First Post Date:
2022-05-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2024-12-06
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2025-12-18
Last Update Post Date:
2025-12-19
Last Update Post Date Type:
ESTIMATED